Corcept Therapeutics Says CHMP Recommends EU Approval Of Relacorilant With Nab-Paclitaxel For Platinum-Resistant Ovarian Cancer; EC Decision Expected In Q4 2026

Benzinga Newsdesk www.benzinga.com Positive 83.6%

Neg 0% Neu 0% Pos 83.6%

Comments

No comments yet. Be the first!